Loading page
Loading page
Loading substance route
Insufflated administration is ineffective.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tapentadol has high abuse potential comparable to other strong μ-opioid receptor agonists such as morphine, oxycodone, and hydromorphone. It is commonly abused, misused, and diverted; human abuse liability studies found 50 mg of tapentadol produces opioid effects comparable to 4 mg of hydromorphone. Its water solubility enables abuse via snorting, inhaling, or injection, which significantly increases risk of dangerous consequences.
Physical dependence develops with regular use, and withdrawal symptoms may be more intense and prolonged compared to typical opioids such as codeine or oxycodone due to tapentadol's dual mechanism as both an opioid agonist and norepinephrine reuptake inhibitor. Withdrawal symptoms include anxiety, restlessness, fever, chills, joint pain, nausea, vomiting, stomach cramps, sweating, tremor, and insomnia. Gradual tapering is recommended rather than abrupt cessation.
The intraperitoneal lowest published toxic dose (TDLO) in rats is 10 mg/kg. Acute overdose is characterized by respiratory depression progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, pulmonary edema, bradycardia, hypotension, partial or complete airway obstruction, and death. Marked mydriasis rather than miosis may be seen due to severe hypoxia in overdose situations.
Respiratory depression is the primary life-threatening toxicity and occurs through direct suppression of brainstem respiratory centers; this effect is dose-dependent and represents the main cause of death in overdose.
Hypotension and bradycardia may occur, particularly at higher doses or in overdose situations; these effects are generally manageable with supportive care.
Reduced gastrointestinal motility commonly results in constipation, nausea, and vomiting during therapeutic use; studies indicate tapentadol causes less constipation and nausea compared with oxycodone.
Tapentadol has been demonstrated to reduce the seizure threshold and is contraindicated in people with epilepsy or who are otherwise prone to seizures. Risk is elevated in patients with head trauma, metabolic disorders, or those undergoing alcohol and drug withdrawal.
Tapentadol was developed by the German pharmaceutical company Grünenthal during the late 1980s. The research team, led by chemist Helmut Buschmann, used tramadol as their starting point—a compound the same company had created in 1962. Their objective was to design a molecule with specific…
Approved by the FDA on November 20, 2008, with the extended-release formulation receiving approval on August 26, 2011. Classified as a narcotic analgesic with recognized high potential for misuse and abuse. Due to addiction risks, tapentadol is reserved for patients for whom alternative treatment options are inadequate or unavailable.
11 sources cited